Business Wire

SynteractHCR Names Steve Powell as Chief Executive Officer

17.7.2017 13:00 | Business Wire

Del

SynteractHCR Holdings Corporation today announced that Steve Powell has been appointed chief executive officer, effective July 10, 2017. Mr. Powell succeeds Wendel Barr, who departs SynteractHCR after six years as CEO. A portfolio company of Amulet Capital Partners, LP, SynteractHCR is a leading, international contract research organization (CRO) focused on Phase I-IV clinical trials for innovative biopharma clients in the U.S., Europe and Asia.

Mr. Powell has more than 25 years of executive leadership experience in both the CRO and pharma/biotech industries. Drawing on this strong base of expertise, he will direct the overall company strategy, positioning, processes and performance.

“Steve Powell is a respected leader who has built an impressive track record of delivering results, both strategically and operationally, with deep involvement across all facets of late stage clinical research,” said Ramsey Frank, partner and co-founder of Amulet. “As large and mid-sized CROs consolidate, SynteractHCR has a unique opportunity to become a dominant CRO focused on the needs of highly innovative, pharma and biotech customers. Under Steve’s leadership, SynteractHCR will be in position to take full advantage of this opportunity.”

Mr. Powell joins SynteractHCR from ERT, having come to ERT through its acquisition of Exco InTouch in December 2016. As president and COO of Exco InTouch, a leading provider of patient engagement, data capture and digital health solutions, Mr. Powell managed all aspects of operational delivery and technology development. While at ERT, he managed a leading product line, which provided an integrated data and analytics platform. Prior to Exco InTouch/ERT, Mr. Powell served as executive vice president, Clinical Informatics and Late Phase Services at PRA Health Sciences for over eight years where he was instrumental in that company’s global expansion from 2,000 to more than 10,000 employees. Prior to joining PRA in 2006, he held several leadership positions across the health care, technology and CRO industries.

Mr. Frank added, “We want to thank Wendel Barr for his tremendous contributions to SynteractHCR, and for playing a key role in shaping the company over the last six years. The company has benefited greatly from his leadership."

Mr. Powell noted that SynteractHCR is well positioned to capitalize on changes in the industry, with its ability to provide flexible, high quality service and strategic guidance to address the needs of pharma and biotech customers: “I am excited to join SynteractHCR at this pivotal time in its growth. The company is a leading CRO with global scale, excellent momentum, and a strong commitment to operational excellence for its customers in all phases of clinical development. I'm looking forward to working with our talented team and with our customers, as well as with Amulet, to take SynteractHCR to the next level.”

About SynteractHCR

SynteractHCR is a full-service international contract research organization (CRO) with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, immunotherapy, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision” philosophy and core values, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data to help bring tomorrow’s treatments to patients.

About Amulet Capital Partners, LP

Amulet Capital Partners, LP is a middle-market private equity investment firm based in Greenwich, CT, focused exclusively on the healthcare sector. Amulet seeks to achieve long-term capital appreciation through privately negotiated investments in companies. Amulet Capital Partners focuses on those segments it believes have the most attractive long-term fundamentals with a target investment size generally between $25 million to $150 million. Amulet Capital Partners' investment team has approximately 40 years of private equity experience. For additional information, please visit www.amuletcapital.com.

Contact information

Contact for SynteractHCR:
Beth Walsh, 760-230-2424
beth@clearpointagency.com
or
Contact for Amulet Capital Partners:
Melissa Sheer, 917-690-2199
melissa@kentplacellc.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Major Terrorist Plot Foiled in Saudi Arabia, Ministry of Interior Announces21.7.2017 18:33Pressemelding

The following is a statement from Saudi Arabia’s Ministry of Culture and Information: This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170721005575/en/ Weapons and other items found in the possession of the three terrorists are an indication of the ugliness and severity of the acts of terrorism they were planning to carry out, victimizing innocent lives and private and public property. (Photo: ME NewsWire) The Saudi Ministry of Interior has announced that a major terrorist attack was prevented by security services in the city of Saihat in the Qatif governorate. On the evening of Friday, July 14th, security services intercepted a stolen Toyota Corolla vehicle in a busy, built-up district of the city. As the stolen vehicle was surrounded by security services, three men in the ca

Janssen Receives Positive CHMP Opinion for SYMTUZA™ The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV21.7.2017 12:09Pressemelding

Janssen-Cilag International NV (Janssen) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for SYMTUZA™ (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]), a once-daily darunavir-based single tablet regimen (STR). If approved, it will be the only darunavir-based STR indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents aged 12 years and older with body weight of at least 40 kg, with genotypic testing guiding use. This STR combines the proven efficacy and durability of darunavir with the improved renal laboratory and bone mineral density profile of F/TAF as compared to F/TDF (tenofovir disoproxil fumarate), and will be the only treatment that could deliver the adherence advantag

Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (Telotristat Ethyl), for the Treatment of Carcinoid Syndrome Diarrhea in Patients Inadequately Controlled by Somatostatin Analogue Therapy21.7.2017 11:26Pressemelding

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion recommending the approval of Xermelo® (telotristat ethyl) 250 mg three times a day (tid) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy. The CHMP positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for use in the 28 countries of the European Union, as well as Norway, Liechtenstein and Iceland. David Meek, Chief Executive Officer of Ipsen, said: “The positive CHMP opinion for Xermelo ® is an important milestone towards providing innovative s

NRI Secure Launches Japan's First "Blockchain Assessment" Service21.7.2017 07:00Pressemelding

NRI SecureTechnologies, Ltd. (President: Jun Odashima; hereinafter NRI Secure), a leading provider of information security solutions in Japan, has begun providing Japan’s first-ever*1 “Blockchain Assessment,” a security Assessment service designed for systems and services which use blockchain technology*2. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170721005012/en/ Overview of the "Blockchain Assessment" Service (Graphic: Business Wire) As the blockchain technology has become more widespread, the presence of security-related vulnerabilities has also become increasingly apparent. In particular, with regard to smart contracts, *3 one of a constituent element of services using the blockchain, a cyberattack carried out on any vulnerable programs could lead to major threats or eve

Business Figures for the First Half of 2017: Sartorius Continues to Grow21.7.2017 05:00Pressemelding

Sartorius (FWB:SRT), a leading international laboratory and pharmaceutical equipment supplier, continues on the growth track. In the first half of 2017, solid organic business development and two acquisitions led to a significant increase in sales revenue and earnings1. "Sartorius has continued its dynamic, profitable development," said CEO and Executive Board Chairman Dr. Joachim Kreuzburg in commenting on the company's first-half performance. "Both divisions achieved solid organic growth in an environment that was especially challenging in North America, and have made quick progress in integrating the businesses most recently acquired. In the Lab Products & Services Division, the bioanalytics unit newly created by our acquisitions has already contributed significant revenues and earnings. We see further considerable growth potential ahead for this business just as for the

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom